Chemed vs AMN Healthcare Services: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chemed Corp (CHE)

Q3 202624 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

August 202624 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

Latest24 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

AMN Healthcare Services Inc (AMN)

Q3 202624 Jun – 15 Sep 2026

▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.
New partnership expands AMN's AI-driven offerings, a key growth driver.
Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.
Core staffing demand rebound is the main force behind AMN's improving results.
Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.
Profit swing and upbeat guidance directly lift earnings expectations and stock price.
Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.
Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

August 202624 Jun – 15 Sep 2026

▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.
New partnership expands AMN's AI-driven offerings, a key growth driver.
Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.
Core staffing demand rebound is the main force behind AMN's improving results.
Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.
Profit swing and upbeat guidance directly lift earnings expectations and stock price.
Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.
Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

Latest24 Jun – 15 Sep 2026

▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.
New partnership expands AMN's AI-driven offerings, a key growth driver.
Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.
Core staffing demand rebound is the main force behind AMN's improving results.
Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.
Profit swing and upbeat guidance directly lift earnings expectations and stock price.
Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.
Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.